RPL21P28: A Promising Drug Target / Biomarker (G100131205)

Target Name: RPL21P28

NCBI ID: G100131205

RPL21P28

Other Name(s): RPL21_8_160 | ribosomal protein L21 pseudogene 28 | Ribosomal protein L21 pseudogene 28

RPL21P28: A Promising Drug Target / Biomarker

The protein RPL21P28 is a key regulator of the Replication Protein Complex (RPC), which is responsible for ensuring the accurate replication of DNA in eukaryotic cells. The RPC plays a crucial role in the regulation of DNA replication, repair, and maintenance, and is composed of a variety of proteins that work together to ensure the efficiency of these processes.

One of the RPC proteins is RPL21, which is a key component of the RPC and is involved in the regulation of DNA replication. RPL21P28 is a regulatory subunit of RPL21 that is responsible for regulating the activity of RPL21.

The RPL21P28 protein is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for the regulation of the activity of RPL21, while the C-terminal cytoplasmic domain is involved in the interaction with other RPC proteins.

The N-terminal transmembrane domain of RPL21P28 is a protein that is composed of multiple predicted transmembrane domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in the regulation of the activity of RPL21, while the transmembrane domain is responsible for the regulation of the movement of RPL21 into the cytoplasm.

The C-terminal cytoplasmic domain of RPL21P28 is a protein that is composed of a single predicted transmembrane domain. This domain is involved in the interaction with other RPC proteins, including RPL23, which is a protein that is involved in the regulation of DNA replication.

The RPL21P28 protein is involved in the regulation of DNA replication because it is a key regulator of the RPC, which is responsible for ensuring the accurate replication of DNA in eukaryotic cells. The RPC is composed of a variety of proteins that work together to ensure the efficiency of these processes, and the RPL21P28 protein is an important component of this complex.

The RPL21P28 protein is also a potential drug target or biomarker because it is involved in the regulation of DNA replication, which is a critical process for the survival of many organisms. Therefore, the study of the RPL21P28 protein and its function in the RPC is of great interest and importance for the development of new therapeutics for a variety of diseases.

Conclusion

In conclusion, the RPL21P28 protein is a key regulator of the Replication Protein Complex and is involved in the regulation of DNA replication. The RPL21P28 protein is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for the regulation of the activity of RPL21, while the C-terminal cytoplasmic domain is involved in the interaction with other RPC proteins.

The RPL21P28 protein is a potential drug target or biomarker because it is involved in the regulation of DNA replication, which is a critical process for the survival of many organisms. Therefore, the study of the RPL21P28 protein and its function in the RPC is of great interest and importance for the development of new therapeutics for a variety of diseases.

Protein Name: Ribosomal Protein L21 Pseudogene 28

The "RPL21P28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL21P28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets